Voyager Therapeutics, Inc. (VYGR) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Voyager Therapeutics reported revenue of $40.4M, down 49.5% from $80.0M the year before. Net income was -$119.7M (a -296.5% net margin), or -$2.04 per diluted share. Operating margin was -326.6%. Operating activities generated -$132.5M of cash, leaving -$135.1M of free cash flow. At fiscal year end, Voyager Therapeutics held $252.3M in total assets against $56.2M in total liabilities, including $65.3M of cash and equivalents.
Open the full interactive Voyager Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Voyager Therapeutics Key Stats
| Share Price | $2.15 |
|---|---|
| Market Cap | $130.2M |
| Revenue YoY Growth | -49.5% |
| 52-Week Range | $2.15 – $5.33 |
| Shares Outstanding | 60.5 million (basic, 2026 Q2) |
Voyager Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $171.1M | $37.4M | $40.9M | $250.0M | $80.0M | $40.4M |
| Operating Income | $27.4M | -$73.6M | -$50.8M | $122.0M | -$83.3M | -$131.8M |
| Pre-Tax Income | $36.7M | -$71.2M | -$46.4M | $133.7M | -$64.3M | -$119.6M |
| Income Tax | — | — | $16,000 | $1.4M | $665,000 | $144,000 |
| Net Income | $36.7M | -$71.2M | -$46.4M | $132.3M | -$65.0M | -$119.7M |
| Diluted EPS | $0.98 | -$1.89 | -$1.21 | $2.97 | -$1.13 | -$2.04 |
Voyager Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $13.4M | $15.3M | $2.6M | $3.2M |
| Net Income | -$27.9M | -$27.4M | -$27.9M | -$24.5M |
| Diluted EPS | -$0.47 | -$0.47 | -$0.47 | -$0.40 |
Voyager Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $104.4M | $117.4M | $99.0M | $68.8M | $71.4M | $65.3M |
| Current Assets | $197.8M | $136.7M | $124.5M | $319.7M | $276.8M | $202.7M |
| Total Assets | $261.6M | $193.9M | $159.4M | $351.3M | $393.1M | $252.3M |
| Current Liabilities | $26.8M | $51.0M | $72.6M | $64.5M | $49.8M | $26.5M |
| Total Liabilities | $107.3M | $98.8M | $100.3M | $115.0M | $93.3M | $56.2M |
| Shareholders' Equity | $154.3M | $95.1M | $59.0M | $236.3M | $299.8M | $196.1M |
Voyager Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$96.7M | -$53.5M | -$12.5M | $77.9M | -$15.3M | -$132.5M |
| Cash From Investing | $113.0M | $65.9M | -$7.3M | -$141.6M | -$94.9M | $125.4M |
| Cash From Financing | $3.2M | $612,000 | $1.1M | $33.6M | $114.0M | $816,000 |
| Free Cash Flow | -$108.8M | -$55.1M | -$15.0M | $74.7M | -$18.8M | -$135.1M |
Figures from Voyager Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Voyager Therapeutics financials page for every line item.
Voyager Therapeutics Company Profile
| Ticker | VYGR |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Lexington, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer, smaller reporting company |
| SEC CIK | 0001640266 |
Frequently Asked Questions
What was Voyager Therapeutics' revenue in fiscal 2025?
Voyager Therapeutics (VYGR) reported revenue of $40.4M for fiscal 2025.
What is Voyager Therapeutics' annual revenue history?
Voyager Therapeutics' annual revenue by fiscal year: 2020: $171.1M; 2021: $37.4M; 2022: $40.9M; 2023: $250.0M; 2024: $80.0M; 2025: $40.4M.
What was Voyager Therapeutics' net income in fiscal 2025?
Voyager Therapeutics reported net income of -$119.7M for fiscal 2025.
What was Voyager Therapeutics' earnings per share (EPS) in fiscal 2025?
Voyager Therapeutics' diluted EPS was -$2.04 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Voyager Therapeutics generate in fiscal 2025?
Voyager Therapeutics generated -$135.1M of free cash flow in fiscal 2025.
What was Voyager Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Voyager Therapeutics reported revenue of $3.2M.
How many shares of Voyager Therapeutics are outstanding?
Voyager Therapeutics reported a weighted average of 60.5 million basic shares outstanding in 2026 Q2.
What is Voyager Therapeutics' market cap?
Based on its latest closing price, Voyager Therapeutics (VYGR) has a market capitalization of about $130.2M.
When does Voyager Therapeutics' fiscal year end?
Voyager Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Voyager Therapeutics headquartered?
Voyager Therapeutics lists its business address in Lexington, Massachusetts in its SEC filings.
Voyager Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →